Why are the EU investigating TikTok? π
Plus a biotech start-up has just made significant steps towards cheaper insulin π
Hey π
Egress stand at the forefront of the security sector, pushing the boundaries of what technology can achieve through constant innovation and delivering unparalleled software solutions. By empowering their engineers with ownership throughout the entire software delivery lifecycle, embracing a collaborative and transparent design approach, and continuously integrating the latest and greatest technology - from core staples like C# .NET, JavaScript, and MS SQL on Azure to adventurous ventures into distributed processing, machine learning, and AI - Egress ensures its team operates with cutting-edge tools. This engineer-led strategy not only guarantees the optimal technology selection for each project but also fosters professional growth, making Egress a beacon of innovation in the tech landscape.
Egress are hiring on Haystack. Check out their cultural values, engineering practices and more on the Haystack app π²
π Big Tech & Startup
The European Union has initiated a formal investigation into TikTok, focusing on its compliance with the Digital Services Act, with a particular focus on the protection of children and other potential violations. The investigation will scrutinise TikTok's features, systems, and policies, especially its age verification tools and the transparency around advertisements. TikTok, owned by ByteDance and boasting nearly 136 million monthly active users in the EU, has expressed its commitment to user safety, particularly for teens. This move by the EU underscores the stringent regulatory environment facing social media platforms, aiming to safeguard online rights and ensure responsible content management.
π Science & Futuristic Tech
In an innovative leap for diabetes care, a biotech startup, rBIO, introduces a groundbreaking method to produce insulin more cost-effectively through biosimilar drugs. Their flagship product, R-biolin, is set to revolutionise insulin accessibility by doubling production yields using novel bacterial strains, thus addressing the imminent supply-demand crisis for insulin. As rBIO gears up for clinical trials to validate R-biolin against existing treatments, their approach not only promises a significant reduction in insulin costs but also aims to disrupt the $90 billion insulin market, making diabetes management more affordable worldwide.
βοΈ Miscellaneous
Air Canada have lost a court case after their AI chatbot made up itβs own refund policy
A dead satellite is hurtling back to Earth and no-one knows where it will land
How much energy does AI actually consume?
π₯ Trending New Roles
Product Executive @ tombola
Sunderland | Hybrid/Remote
Junior Data Science Engineer @ Atom bank
Durham | Hybrid/Remote
Senior Software Engineer @ Egress
Sunderland, London | Hybrid
Lead Analyst @ Dunelm
Leicester, London | Hybrid
Senior Engineering Manager @ American Express
London, Burgess Hill | Hybrid
Data Analyst @ PayPoint
Welwyn Garden City | Hybrid